Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database [Erratum]

This article refers to:

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

Baer PA, Aumais G, Ewara EM, et al. Patient Prefer Adherence. 2018;12:1805–1814.

On page 1805, the affiliations were incorrectly listed. The correct affiliations should be as follows:

Philip A Baer¹

Guy Aumais²

Emmanuel M Ewara³

Majed Khraishi⁴

A Marilise Marrache⁵

Remo Panaccione⁶

John P Wade⁷

John K Marshall⁸

¹Baer Weinberg MPC, Scarborough, ON, ²Department of Medicine, Université de Montréal, Gastro-enterology Unit, Hôpital Maisonneuve-Rosemont, Montréal, QC, ³Government Affairs and Market Access, Janssen Inc., Toronto, ON, ⁴Faculty of Medicine, Division of Rheumatology, Memorial University of Newfoundland and Nexus Clinical Research, St John’s, NL, ⁵Medical Affairs, Janssen Inc., Toronto, ON, ⁶Inflammatory Bowel Disease Unit, Department of Medicine, University of Calgary, Calgary, AB, ⁷Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, BC, ⁸Department of Medicine, Division of Gastroenterology, McMaster University and Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada